PURPOSE: Duchenne muscular dystrophy (DMD) and its treatment by glucocorticoids are associated with secondary osteoporosis, short stature, and delayed puberty. We aimed at exploring the prevalence and subjective burden of these endocrinological complications after the implementation of recommended care protocols. METHODS: A prospective cross-sectional medical report review of boys with DMD followed at the largest pediatric neuromuscular reference center. An online questionnaire survey was part of the study. RESULTS: We included 35 boys with DMD, aged 5.7-19.7 years, most of them on long-term daily glucocorticoid therapy (91%). Vertebral fractures were present in 50% of boys, short stature in 74%, and pubertal delay in 56% of boys. The glucocorticoid treatment duration and cumulative doses were associated with a higher prevalence of short stature, but not with the presence of vertebral fractures or pubertal delay. Areal bone mineral density assessed by densitometry only poorly identified patients with osteoporosis, compared to clear evidence of vertebral fractures by lateral spine radiograph. The boys were most concerned about the risk of fractures. Those in the pubertal age, however, were troubled also by their childish looks. The boys tolerated the surveillance protocols and treatment of complications very well. CONCLUSIONS: Vertebral fractures, short stature, and delayed puberty are very frequent among glucocorticoid-treated boys with DMD. Lateral spine radiograph is a crucial means for bone health assessment, with an even larger yield than densitometry. A questionnaire survey identifies patient needs and improves complex health care.

Department of Pediatric Neurology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague 150 06 5 Úvalu 84 Czech Republic

Department of Pediatrics 2nd Faculty of Medicine Charles University and Motol University Hospital Prague 150 06 5 Úvalu 84 Czech Republic

Department of Rehabilitation and Sports Medicine Charles University and Motol University Hospital Prague 150 06 5 Úvalu 84 Czech Republic

Zobrazit více v PubMed

Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G (2020) Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis 15(1):141. 10.1186/s13023-020-01430-8PMID: 32503598; PMCID: PMC7275323 PubMed DOI PMC

Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY (2016) Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev 2016(5):CD003725. 10.1002/14651858.CD003725.pub4 PubMed DOI PMC

Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K (2010) Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 25(9):1116–1129. 10.1177/0883073810371004Epub 2010 Jun 25. PMID: 20581335 PubMed DOI

Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, DMD Care Considerations Working Group et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17(3):251–267. 10.1016/S1474-4422(18)30024-3 PubMed DOI PMC

Koeks Z, Bladen LC, Salgado D, van Zwet E, Pogoryelova O, McMacken G et al (2017) Clinical outcomes in Duchenne muscular dystrophy: A study of 5345 patients from the TREAT-NMD DMD global database. J Neuromuscul Dis [online] 4(4):293–306 [cit. 2021-11-19]. ISSN 22143599. Dostupné z. 10.3233/JND-170280 PubMed DOI PMC

Bianchi ML, Mazzanti A, Galbiati E, Saraifoger S, Dubini A, Cornelio F et al (2003) Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int 14(9):761–767. 10.1007/s00198-003-1443-y PubMed DOI

Joseph S, Wang C, Bushby K, Guglieri M, Horrocks I, Straub V, UK NorthStar Clinical Network et al (2019) Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UK NorthStar database. JAMA Neurol 76(6):701–709. 10.1001/jamaneurol.2019.0242 PubMed PMC

Tian C, Wong BL, Hornung L, Khoury JC, Miller L, Bange J et al (2016) Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy. Neuromuscul Disord 26(11):760–767 Epub 2016 Aug 22. PMID: 27614576 PubMed DOI

Bell JM, Shields MD, Watters J, Hamilton A, Beringer T, Elliott M et al (2017) Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. Cochrane Database Syst Rev 1(1):CD010899. 10.1002/14651858.CD010899.pub2 PubMed DOI PMC

Ward LM, Weber DR (2019) Growth, pubertal development, and skeletal health in boys with Duchenne muscular dystrophy. Curr Opin Endocrinol Diabetes Obes 26(1):39–48. 10.1097/MED.0000000000000456 PubMed DOI PMC

Bianchi ML, Biggar D, Bushby K, Rogol AD, Rutter MM, Tseng B (2011) Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord 21(4):298–303. 10.1016/j.nmd.2011.02.006 PubMed DOI

Simm PJ, Biggin A, Zacharin MR, Rodda CP, Tham E, Siafarikas A, APEG Bone Mineral Working Group (2018) Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health 54(3):223–233. 10.1111/jpc.13768 PubMed DOI

Larson CM, Henderson RC (2000 Jan-Feb) Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 20(1):71–74 PMID: 10641693 PubMed

McDonald DG, Kinali M, Gallagher AC, Mercuri E, Muntoni F, Roper H et al (2002) Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol 44(10):695–8. 10.1017/s0012162201002778 PubMed DOI

Singh A, Schaeffer EK, Reilly CW (2018) Vertebral fractures in Duchenne muscular dystrophy patients managed with deflazacort. J Pediatr Orthop 38(6):320–324. 10.1097/BPO.0000000000000817 PubMed DOI

Crabtree NJ, Adams JE, Padidela R, Shaw NJ, Högler W, Roper H et al (2018) Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen. Bone 116:181–186 Epub 2018 Jul 25. PMID: 30055340 PubMed DOI

Mayo AL, Craven BC, McAdam LC, Biggar WD (2012) Bone health in boys with Duchenne muscular dystrophy on long-term daily deflazacort therapy. Neuromuscul Disord 22(12):1040–1045. 10.1016/j.nmd.2012.06.354 PubMed DOI

Bothwell JE, Gordon KE, Dooley JM, MacSween J, Cummings EA, Salisbury S (2003) Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr (Phila). ;42(4):353-6. 10.1177/000992280304200408. PMID: 12800730 PubMed

Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA et al (2017) The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int 28(2):597–608. 10.1007/s00198-016-3774-5Epub 2016 Oct 24. PMID: 27774565 PubMed DOI

Wood CL, Straub V, Guglieri M, Bushby K, Cheetham T (2016) Short stature and pubertal delay in Duchenne muscular dystrophy. Arch Dis Child 101(1):101–6. 10.1136/archdischild-2015-308654 PubMed DOI

Nagel BH, Mortier W, Elmlinger M, Wollmann HA, Schmitt K, Ranke MB (1999) Short stature in Duchenne muscular dystrophy: a study of 34 patients. Acta Paediatr 88(1):62–65 PMID: 10090550 PubMed DOI

West NA, Yang ML, Weitzenkamp DA, Andrews J, Meaney FJ, Oleszek J et al (2013) Patterns of growth in ambulatory males with Duchenne muscular dystrophy. J Pediatr 163(6):1759–1763e1 Epub 2013 Oct 6. PMID: 24103921 PubMed DOI

Sarrazin E, von der Hagen M, Schara U, von Au K, Kaindl AM (2014) Growth and psychomotor development of patients with Duchenne muscular dystrophy. Eur J Paediatr Neurol 18(1):38–44 Epub 2013 Sep 25. PMID: 24100172 PubMed DOI

Matsumoto M, Awano H, Lee T, Takeshima Y, Matsuo M, Iijima K (2017) Patients with Duchenne muscular dystrophy are significantly shorter than those with Becker muscular dystrophy, with the higher incidence of short stature in Dp71 mutated subgroup. Neuromuscul Disord 27(11):1023–1028 Epub 2017 Jun 19. PMID: 28734761 PubMed DOI

Wood CL, Page J, Foggin J, Guglieri M, Straub V, Cheetham TD. The impact of testosterone therapy on quality of life in adolescents with Duchenne muscular dystrophy. Neuromuscul Disord. Sep 25:S0960-8966(21)00653-2. doi:, Colletto D, Vainzof GM, Duaik M, Zatz MC (2021) M. Short stature in Duchenne muscular dystrophy. Growth Regul. 1991;1(1):11 – 5. PMID: 1842555

Rapisarda R, Muntoni F, Gobbi P, Dubowitz V (1995) Duchenne muscular dystrophy presenting with failure to thrive. Arch Dis Child 72:437–438 PubMed DOI PMC

Chrysis D, Ritzen EM, Sävendahl L (2003) Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes. J Endocrinol 176(3):331–7. 10.1677/joe.0.1760331 PubMed DOI

Jux C, Leiber K, Hügel U, Blum W, Ohlsson C, Klaus G et al (1998) Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-i production and expression of GH- and IGF-i-receptor in cultured rat chondrocytes. Endocrinology 139(7):3296–305. 10.1210/endo.139.7.6099 PubMed DOI

Mazziotti G, Giustina A (2013) Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 9(5):265–76. 10.1038/nrendo.2013.5 PubMed DOI

Rutter MM, Collins J, Rose SR, Woo JG, Sucharew H, Sawnani H et al (2012) Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord 22(12):1046–1056. 10.1016/j.nmd.2012.07.009 PubMed DOI

Rosen H, Jameel ML, Barkan AL (1988) Dexamethasone suppresses gonadotropin-releasing hormone (GnRH) secretion and has direct pituitary effects in male rats: differential regulation of GnRH receptor and gonadotropin responses to GnRH. Endocrinology 122(6):2873–80. 10.1210/endo-122-6-2873 PubMed DOI

Annexstad EJ, Bollerslev J, Westvik J, Myhre AG, Godang K, Holm I et al (2019) The role of delayed bone age in the evaluation of stature and bone health in glucocorticoid treated patients with Duchenne muscular dystrophy. Int J Pediatr Endocrinol 2019:4. 10.1186/s13633-019-0070-0Epub 2019 Dec 23. PMID: 31889957; PMCID: PMC6927168 PubMed DOI PMC

Denger B, Kinnett K, Martin A, Grant S, Armstrong C, Khodyakov D (2019) Patient and caregiver perspectives on guideline adherence: the case of endocrine and bone health recommendations for Duchenne muscular dystrophy. Orphanet J Rare Dis. 10.1186/s13023-019-1173-7 PubMed DOI PMC

Parente L (2017) Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol 18(1):1. 10.1186/s40360-016-0111-8PMID: 28057083; PMCID: PMC5216559 PubMed DOI PMC

Tanner JM, Goldstein H, Whitehouse RH (1970) Standards for children’s height at ages 2–9 years allowing for heights of parents. Arch Dis Child 45(244):755–762. 10.1136/adc.45.244.755PMID: 5491878; PMCID: PMC1647404 PubMed DOI PMC

PROGRAM RUSTCZ KE STAŽENÍ. (n.d.). Státní zdravotní ústav. Accessed April 1 (2020) from https://szu.gov.cz/publikace-szu/data/hodnoceni-rustu-a-vyvoje/program-rustcz-ke-stazeni/

Vignerová J, Riedlová J, Bláha P, Kobzová J, Krejčovský L, Brabec M et al (2006) Celostátní antropologický Výzkum Dětí a Mládeže 2001. Česká republika. Souhrnné Výsledky. PřF UK, SZÚ, Praha, p 238

Soucek O, Lebl J, Snajderova M, Kolouskova S, Rocek M, Hlavka Z et al (2011) Bone geometry and volumetric bone mineral density in girls with Turner syndrome of different pubertal stages. Clin Endocrinol (Oxf). ;74(4):445 – 52. 10.1111/j.1365-2265.2010.03955.x. PMID: 21138463 PubMed

Stříbrná T, Macek M, Laboratorní (2022) příručka. https://www.fnmotol.cz/wp-content/uploads/ilp-ublg-01-2016-laboratorni-prirucka-12.pdf. Published January 24, Version 12. Accessed December 4, 2022

Gordon CM, Leonard MB, Zemel BS, International Society for Clinical Densitometry (2013). Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom. 2014 Apr-Jun;17(2):219 – 24. doi: 10.1016/j.jocd.2014.01.007. Epub 2014 Mar 20. Erratum in: J Clin Densitom. 2014 Oct-Dec;17(4):517. PMID: 24657108 PubMed

Wood CL, Hollingsworth KG, Hughes E, Punniyakodi S, Muni-Lofra R, Mayhew A et al (2021) Pubertal induction in adolescents with DMD is associated with high satisfaction, gonadotropin release and increased muscle contractile surface area. Eur J Endocrinol 184(1):67–79. 10.1530/EJE-20-0709 PubMed DOI

Survio (2021, March 3). Vytvořit dotazník. https://www.survio.com/l-cs-14-vytvorit-dotaznik?campaignid=69428100&keywordid=kwd-43200881820&keyword=survio&matchtype=e&adgroupid=22060879860&adposition=&device=c&trc_cp=CZ-CZ&utm_source=google&utm_medium=cpc&utm_campaign=S-CZ-CZ-SEA&utm_term=survio&utm_campaign=S-CZ-CZ-SEA&utm_source=adwords&utm_medium=ppc&hsa_acc=8232418607&hsa_cam=69428100&hsa_grp=22060879860&hsa_ad=720322853466&hsa_src=g&hsa_tgt=kwd-43200881820&hsa_kw=survio&hsa_mt=e&hsa_net=adwords&hsa_ver=3&gad_source=1&gclid=EAIaIQobChMIvY6arInSigMVQJ6DBx1hXTiTEAAYASAAEgJDefD_BwE

R Core Team (2023) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/

Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, DMD Care Considerations Working Group et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17(4):347–361. 10.1016/S1474-4422(18)30025-5 PubMed DOI PMC

Joseph S, Wang C, Di Marco M, Horrocks I, Abu-Arafeh I, Baxter A et al (2019) Fractures and bone health monitoring in boys with Duchenne muscular dystrophy managed within the Scottish Muscle Network. Neuromuscul Disord 29(1):59–66 PubMed DOI

Suthar R, Reddy BVC, Malviya M, Sirari T, Attri SV, Patial A et al (2021) Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study. J Pediatr Endocrinol Metab 34(5):573–581. 10.1515/jpem-2020-0680 PubMed DOI

Clark EM, Ness AR, Bishop NJ, Tobias JH (2006) Association between bone mass and fractures in children: a prospective cohort study. J Bone Miner Res 21(9):1489–1495. 10.1359/jbmr.060601 PubMed DOI PMC

Henderson RC, Berglund LM, May R, Zemel BS, Grossberg RI, Johnson J et al (2010) The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy. J Bone Min Res 25(3):520–526. 10.1359/jbmr.091007PMID: 19821773; PMCID: PMC3153393 PubMed DOI PMC

Lamb MM, West NA, Ouyang L, Yang M, Weitzenkamp D, James K et al (2016) Muscular dystrophy surveillance, research, and tracking network (MD STARnet). Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular dystrophy. J Pediatr 173:207–213e3. 10.1016/j.jpeds.2016.02.067Epub 2016 Mar 30. PMID: 27039228; PMCID: PMC5100357 PubMed DOI PMC

Bodor M, McDonald CM (2013) Why short stature is beneficial in Duchenne muscular dystrophy. Muscle Nerve 48(3):336–42. 10.1002/mus.23793 PubMed DOI

Banks GB, Chamberlain JS (2008) The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol. ;84:431 – 53. 10.1016/S0070-2153(08)00609-1. PMID: 19186250 PubMed

Zatz M, Rapaport D, Vainzof M, Rocha JM, Pavanello Rde C, Colletto GM et al (1988) Relation between height and clinical course in Duchenne muscular dystrophy. Am J Med Genet. ;29(2):405 – 10. doi: 10.1002/ajmg.1320290223. PMID: 3354613 PubMed

Rohlenová M, Machová K, Stará V, Hedvičáková P, Zieg J, Doušová T et al (2020) Characteristics of a cohort of boys with Duchenne and Becker muscular dystrophies – a study from a single neuromuscular centre. Česká a Slovenská neurologie a neurochirurgie [online]. 83/116(3):305–314 ISSN 12107859. 10.14735/amcsnn2020305

Dooley JM, Bobbitt SA, Cummings EA (2013) The impact of deflazacort on puberty in Duchenne muscular dystrophy. Pediatr Neurol 49(4):292–3. 10.1016/j.pediatrneurol.2013.05.004 PubMed DOI

Merlini L, Gennari M, Malaspina E, Cecconi I, Armaroli A, Gnudi S et al (2012) Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 45(6):796–802. 10.1002/mus.23272 PubMed DOI

Lee SL, Lim A, Munns C, Simm PJ, Zacharin M (2020) Effect of Testosterone Treatment for Delayed Puberty in Duchenne Muscular Dystrophy. Horm Res Paediatr. ;93(2):108–118. 10.1159/000508290. Epub 2020 Jul 1. PMID: 32610327 PubMed